Search company, investor...
Allon Therapeutics company logo

Allon Therapeutics


Acquired | Acquired

Total Raised




About Allon Therapeutics

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human efficacy trials underway pursuing three large underserved markets: Alzheimer's disease, schizophrenia and cognitive impairment.

Headquarters Location

1168 Hamilton Street Suite 506

Vancouver, British Columbia, V6B 2S2,


Missing: Allon Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Allon Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Allon Therapeutics Patents

Allon Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Proteins, Transcription factors, Piperidines, Syndromes


Application Date


Grant Date



Related Topics

Autoimmune diseases, Proteins, Transcription factors, Piperidines, Syndromes



Allon Therapeutics Frequently Asked Questions (FAQ)

  • Where is Allon Therapeutics's headquarters?

    Allon Therapeutics's headquarters is located at 1168 Hamilton Street, Vancouver.

  • What is Allon Therapeutics's latest funding round?

    Allon Therapeutics's latest funding round is Acquired.

  • How much did Allon Therapeutics raise?

    Allon Therapeutics raised a total of $2.5M.

  • Who are the investors of Allon Therapeutics?

    Investors of Allon Therapeutics include Allon Therapeutics, Linkagene, NDI Capital and BC Advantage Funds.

  • Who are Allon Therapeutics's competitors?

    Competitors of Allon Therapeutics include Intarcia Therapeutics, Rhythm Pharmaceuticals, VistaGen, Pulmatrix, Intercept Pharmaceuticals and 12 more.

Compare Allon Therapeutics to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Inagen Aps

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics


JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Embera NeuroTherapeutics

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.

Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.